靶向BET蛋白提高BCL-2抑制在T细胞急性淋巴细胞白血病中的疗效
该研究以T细胞急性淋巴细胞白血病(T-ALL)为模型,在来自高复发风险或复发患者原代白血病标本及细胞系中进行体外药物筛选,发现venetoclax与BET溴结构域抑制剂JQ1具有协同活性,并在T-ALL细胞系及患者来源异种移植模型中证实该协同作用。其机制可能部分由BET溴结构域抑制急性诱导促凋亡因子BCL2L11并伴随BCL-2减少所介导,最终增强BIM与BCL-2结合。
要点
- 体外药物筛选发现venetoclax与BET溴结构域抑制剂JQ1在T-ALL原代标本和细胞系中具有协同活性。
- 该药物协同作用在T-ALL细胞系及患者来源异种移植模型中得到体内证实。
- 协同效应可能部分由BET溴结构域抑制急性诱导BCL2L11并伴随BCL-2减少、增强BIM与BCL-2结合所介导。
核心结论
- 本研究为在高风险白血病患者特定亚组中开发新型靶向联合治疗提供了依据。
研究设计与样本
- 研究以T细胞急性淋巴细胞白血病(T-ALL)为模型系统,在来自高复发风险或复发患者原代白血病标本及细胞系中进行体外药物筛选,并使用T-ALL细胞系和患者来源异种移植模型进行体内验证。
主要发现
- 体外药物筛选显示venetoclax与BET溴结构域抑制剂JQ1在T-ALL原代白血病标本和细胞系中具有协同活性。
- 该药物协同作用在T-ALL细胞系和患者来源异种移植模型的体内实验中得到证实。
- 该联合治疗的获益可能至少部分由BET溴结构域抑制急性诱导促凋亡因子BCL2L11并伴随BCL-2减少所介导,最终增强BIM(由BCL2L11编码)与BCL-2的结合。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Inhibition of anti-apoptotic BCL-2 (B-cell lymphoma 2) has recently emerged as a promising new therapeutic strategy for the treatment of a variety of human cancers, including leukemia. Here, we used T-cell acute lymphoblastic leukemia (T-ALL) as a model system to identify novel synergistic drug combinations with the BH3 mimetic venetoclax (ABT-199). In vitro drug screening in primary leukemia specimens that were derived from patients with high risk of relapse or relapse and cell lines revealed synergistic activity between venetoclax and the BET (bromodomain and extraterminal) bromodomain inhibitor JQ1. Notably, this drug synergism was confirmed in vivo using T-ALL cell line and patient-derived xenograft models. Moreover, the therapeutic benefit of this drug combination might, at least in part, be mediated by an acute induction of the pro-apoptotic factor BCL2L11 and concomitant reduction of BCL-2 upon BET bromodomain inhibition, ultimately resulting in an enhanced binding of BIM (encoded by BCL2L11) to BCL-2. Altogether, our work provides a rationale to develop a new type of targeted combination therapy for selected subgroups of high-risk leukemia patients.
引用
- Peirs S, Frismantas V, Matthijssens F, et al. Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia. Leukemia. 2017. PMID: 28074072. doi:10.1038/leu.2017.10
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。